FDA Approves New Cholesterol Pill

By the Editorial Team · Friday, July 17, 2026

The FDA has approved Lipfendra, Merck’s new oral medication that significantly lowers LDL cholesterol by inhibiting PCSK9, offering an alternative to existing injectable treatments. This approval could reshape cardiovascular care by providing a more convenient option for patients who require additional cholesterol management beyond statins, with Merck aiming to capture a sizable share of the PCSK9 inhibitor market.

The U.S. Food and Drug Administration has approved Lipfendra, a new cholesterol-lowering medication developed by Merck, marking the first pill of its kind designed to significantly reduce low-density lipoprotein (LDL) cholesterol beyond the effects of statins alone. The approval was announced on July 17, 2026.

Lipfendra targets high cholesterol, a key factor in the development of heart attacks and strokes, by inhibiting a protein called PCSK9. This protein impedes the body’s ability to clear LDL cholesterol, often referred to as “bad” cholesterol. While PCSK9 inhibitors have been available for several years, they have primarily been administered via injections, such as Amgen’s Repatha, which generated approximately $3 billion in annual sales.

Clinical trials demonstrated that Merck’s once-daily oral formulation reduced LDL cholesterol levels by up to 60% over a six-month period in adults with or at heightened risk for atherosclerotic cardiovascular disease. Merck Chief Executive Robert Davis emphasized the significance of the pill’s ease of use, stating that the ability to lower cholesterol substantially with an oral medication could transform cardiovascular care in the United States.

Lipfendra is intended to be used alongside statins, a widely prescribed class of cholesterol-lowering drugs including Lipitor and Zocor. Although statins have been effective in reducing the risk of cardiovascular events, they do not work sufficiently for all patients, creating demand for additional treatment options. Other newer therapies include RNA-based injections such as Novartis’s Leqvio, administered twice yearly.

Merck is currently conducting further studies to determine whether Lipfendra’s cholesterol-lowering effects also translate into reductions in heart attacks, strokes, and other cardiovascular events. The drug will be priced at $10.50 per pill, or about $315 for a 30-day supply. However, Merck expects that out-of-pocket costs for insured patients will be substantially lower. The company also plans to offer Lipfendra at discounted rates through TrumpRx.gov, a government-affiliated platform designed to provide prescription drug discounts, though specific pricing details for that program have yet to be finalized.

Market analysts forecast strong demand for Lipfendra, projecting peak annual sales exceeding $5 billion. The convenience of a daily pill combined with significant LDL cholesterol reduction positions Merck to compete in the growing PCSK9 inhibitor market, which has until now been dominated by injectable therapies.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.